Interleukin 6 is essential for in vivo development of B lineage neoplasms.
about
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myelomaIL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cellsMonoclonal antibodies in the treatment of multiple myeloma: current status and future perspectivesPreclinical validation of interleukin 6 as a therapeutic target in multiple myelomaWnt signaling in B-cell neoplasiaInterleukin-6, CD45 and the src-kinases in myeloma cell proliferationCD19 expression and growth inhibition of tumours in human multiple myelomaAn unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth.Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.Chronic inflammation and cytokines in the tumor microenvironment.IL-6 and MYC collaborate in plasma cell tumor formation in mice.STAT signaling in the pathogenesis and treatment of cancerPhase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.IL-6 transgenic mouse model for extraosseous plasmacytoma.Proliferation of immature myeloma cells by interleukin-6 is associated with CD45 expression in human multiple myeloma.Interleukin-6 in bone metastasis and cancer progression.p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB.Epstein-Barr virus associated polymorphic lymphoproliferative disorders occurring in nontransplant settings.Impact of interleukin-6 in hematological malignancies.Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor geneInterleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes.Destabilization of interleukin-6 mRNA requires a putative RNA stem-loop structure, an AU-rich element, and the RNA-binding protein AUF1.Constitutive NF-kappaB activation confers interleukin 6 (IL6) independence and resistance to dexamethasone and Janus kinase inhibitor INCB018424 in murine plasmacytoma cells.Therapeutic effects of thalidomide in myeloma are associated with the expression of fibroblast growth factor receptor 3Interleukin-6 is required for a protective immune response to systemic Escherichia coli infectionSalmonella typhi stimulation of human intestinal epithelial cells induces secretion of epithelial cell-derived interleukin-6.Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.Epidemiology and molecular pathology at crossroads to establish causation: molecular mechanisms of malignant transformation.Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1.IL-6 Contributes to the Defective Osteogenesis of Bone Marrow Stromal Cells from the Vertebral Body of the Glucocorticoid-Induced Osteoporotic Mouse.Context-specific roles for paracrine IL-6 in lymphomagenesis.Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma.Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow.Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus.Deficiency of iPLA₂β Primes Immune Cells for Proinflammation: Potential Involvement in Age-Related Mesenteric Lymph Node LymphomaA Role for PPARgamma in the Regulation of Cytokines in Immune Cells and Cancer.Socs3 maintains the specificity of biological responses to cytokine signals during granulocyte and macrophage differentiation.Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?
P2860
Q24646864-4BD3CC26-AD05-413C-AED5-6C9CE46A776DQ24794588-8D39C270-DBD6-4340-9959-8AC35500F6D5Q26799104-7C8462BA-1E2F-41A6-9318-4BEE6B1C7BA2Q27027729-1C93E220-7072-4FA9-8A16-664A236822DBQ28182311-01FCFE21-D58F-49D7-8A98-BB723026CFBAQ28210841-AF03E5A1-DBE5-4A6B-A1C6-3D9D945280FBQ28217091-DE381B6B-7452-4915-994D-8CD72757EE9EQ30885275-FCAF54F4-66D0-4729-ACB8-4C4A79C663F2Q33411075-1B5A4CA2-01E7-4478-9316-6259A24E0282Q33503487-146860AF-F4D7-435F-8803-EE34DE45444AQ33678275-B7472C38-DADD-484E-858C-39272F17A2FEQ33706389-7F775617-7345-4F33-9846-27BE0FD66AA0Q33712802-D1E777E6-FB4E-4CBC-86EB-401E9E29CE4AQ34009070-1F2D225F-E8C6-4B1A-8FF4-88668F7E60EDQ34009997-9BCDC619-5710-4574-918D-00A641DF138EQ34024246-7FA342C4-7A21-4F6B-8B7D-8122BAA0CF32Q34051820-750E1524-4543-4AF7-B254-AE6206F18749Q34191250-F78D8F66-4C6E-4155-8492-C1933FF0F05FQ34220305-1A20A215-E2BF-4BF7-891D-15A2C6107BB4Q34387624-4176E3AA-9FE4-434E-B3D7-49BE78B8680EQ34389036-0344B9C6-1727-481E-AADC-EE47FA1B3450Q34440657-39ED1BB9-07DB-492E-9F28-14114CFC98FDQ35131515-1766D4D8-F428-4D10-9F22-9C7E1511E880Q35150054-BD725393-D762-4A1A-A8C8-207AB4A349B0Q35166712-CFE815D7-48A1-4B30-AB68-75E4289AED74Q35512179-4C15DB24-65E3-439C-8452-9899B83FCD8DQ35534558-B0188E68-AA20-4D5E-A7B7-E7F4029D543DQ35763419-47199242-2A09-42E5-A977-3C25DB5AF6BFQ35868049-5AF654D3-6DB3-4D58-AA38-6F3EBFD51EC7Q35919276-FA8B9169-E226-4666-AABC-BA60C6961FDFQ36003384-8BE97EA9-E9D9-4E03-9874-F5FADB419DD8Q36162671-3E57679F-2C00-4568-B37B-2C8E12435CA4Q36331908-1AE58B7F-9AEF-40DB-B10B-D4B08FBFAA56Q36376043-C5EB05D9-8C68-420C-8531-1ED7B20B58A2Q36404163-5C663A32-8B5E-4329-9838-DE4B6B1EDE1EQ36416156-D6C98E38-1DB0-4B7D-B909-F21367172744Q36724717-FC471512-7226-4BAB-83F6-287527ECD420Q36915197-82DAF09B-92C5-4A1C-A0EA-04AC25353E8FQ37148370-A5971879-DEB1-4B4B-8F52-C96E4188348CQ37836908-EA42723E-F7D6-4807-BCD2-0F6C2CC94D52
P2860
Interleukin 6 is essential for in vivo development of B lineage neoplasms.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Interleukin 6 is essential for in vivo development of B lineage neoplasms.
@ast
Interleukin 6 is essential for in vivo development of B lineage neoplasms.
@en
type
label
Interleukin 6 is essential for in vivo development of B lineage neoplasms.
@ast
Interleukin 6 is essential for in vivo development of B lineage neoplasms.
@en
prefLabel
Interleukin 6 is essential for in vivo development of B lineage neoplasms.
@ast
Interleukin 6 is essential for in vivo development of B lineage neoplasms.
@en
P2093
P2860
P356
P1476
Interleukin 6 is essential for in vivo development of B lineage neoplasms.
@en
P2093
P2860
P304
P356
10.1084/JEM.182.1.243
P407
P577
1995-07-01T00:00:00Z